While mTOR and TGF‐β signaling inhibitors and drugs targeting metabolic pathways have shown promise in BC therapy,52, 53, 54, 55, 56 their efficacy often encounters challenges such as tumor heterogeneity.29 Here, TGFB1 is linked to neoplasm.